Urocitra-K SR Tablet provides treatment of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones. Through urine alkalization action with citraturic urine, it dissolves the calcium stones, uric acid stones and cystine stones, and inhibits their recurrence.
In combination with extracorporeal shock wave lithotripsy (ESWL), Urocitra-K features superior efficacy, particularly for patients undergoing ESWL and those with recurrent urinary stones.

A long-term administration of Urocitra-K improves tolerance and minimizes adverse effects.
Pharmbio Korea Inc. founded in 1999, is the first company to develop treatment for urinary stones in Korea, and has introduced Urocitra, an innovative product for urology, gastroenterology, general surgery, and ob-gyn, among others. Pharmbio Korea has been recognized as one of the most influential companies in the above-mentioned therapeutic areas, and was accredited by the by Korea’s Ministry of Knowledge and Economy in 2011 for its contributions to public health.

Korean-Products.com | Blog Magazine of Korean products, brands and Goods